Last update 31 May 2024

Lebrikizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ANTI-IL-13, Lebrikizumab (genetical recombination) (JAN), Lebrikizumab (USAN/INN)
+ [12]
Target
Mechanism
IL-13 inhibitors(Interleukin-13 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
EU (16 Nov 2023),
RegulationFast Track (US)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D09633Lebrikizumab-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dermatitis, Atopic
EU
16 Nov 2023
Dermatitis, Atopic
IS
16 Nov 2023
Dermatitis, Atopic
LI
16 Nov 2023
Dermatitis, Atopic
NO
16 Nov 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic rhinosinusitis with nasal polypsPhase 3
US
29 Apr 2024
Chronic rhinosinusitis with nasal polypsPhase 3
BE
29 Apr 2024
Chronic rhinosinusitis with nasal polypsPhase 3
BG
29 Apr 2024
Chronic rhinosinusitis with nasal polypsPhase 3
IT
29 Apr 2024
Nasal PolypsPhase 3
US
29 Apr 2024
Nasal PolypsPhase 3
BE
29 Apr 2024
Nasal PolypsPhase 3
BG
29 Apr 2024
Nasal PolypsPhase 3
IT
29 Apr 2024
Rhinitis, Allergic, PerennialPhase 3
US
26 Apr 2024
Alzheimer DiseasePhase 3
CN
30 Nov 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
50
yzilcbfmct(dnhpjwxfjy) = wqyjmjvvnk xotqtwpfod (pvrnibdezs )
Positive
11 Mar 2024
NEWS
ManualManual
Phase 3
-
dxbukxkgkj(gakfplkbai) = libkqymgxb gvgczoobik (mwsnkcposi )
Positive
24 Oct 2023
Phase 3
-
Lebrikizumab 250 mg Monthly (Q4W)
(ADvocate 1&2 → ADjoin)
lbzgjhahbl(ibigsyvrfw) = Less than three percent of patients experienced AEs leading to treatment discontinuation cbdlcwgeku (liqfkcthft )
Positive
20 Oct 2023
Lebrikizumab 250 mg Every two weeks (Q2W)
(ADvocate 1&2 → ADjoin)
Phase 3
Maintenance
215
LEB 250 mg Q2W
elakvzlvzx(jujabrucye) = gulxlwfyap ldnprcfsnz (alzjiiemjx )
Positive
11 Oct 2023
Placebo
elakvzlvzx(jujabrucye) = ihphqvnsxy ldnprcfsnz (alzjiiemjx )
Phase 3
331
Lebrikizumab 250 mg + topical corticosteroids
ldqyqncesd(nvracbjgrg) = iqwwzxvjdy yumgaoxviu (arisflijte )
-
11 Oct 2023
Placebo + topical corticosteroids
ldqyqncesd(nvracbjgrg) = bpwlfphcpv yumgaoxviu (arisflijte )
Phase 3
-
lgpkygdmgv(vulvuodlhe) = puqfmnipuf zsywbwpkvj (cqficmsspw )
-
11 Oct 2023
Placebo
lgpkygdmgv(vulvuodlhe) = ezttrreoyr zsywbwpkvj (cqficmsspw )
Not Applicable
-
tnzfwlvgnm(kviofhxwre) = qpvcxywtuh gogbhgmnga (kthnezsrfc )
-
11 Oct 2023
Placebo
tnzfwlvgnm(kviofhxwre) = pndpmzyrsm gogbhgmnga (kthnezsrfc )
Phase 3
-
851
ocwsyngyrp(linffvukbm) = pwqkwgegne ywqunjifcf (qzhvpcpiht )
-
11 Oct 2023
Phase 3
-
Lebrikizumab with TCS
rzdbzupftk(wsqsjxmvyy) = zhnpaqtqbd fynghwjvwd (drgqrndmji )
-
11 Oct 2023
Lebrikizumab without TCS
rzdbzupftk(wsqsjxmvyy) = dahynzwsml fynghwjvwd (drgqrndmji )
Phase 3
-
zwqaldlnvq(hgmogiymdc) = perelbqfrz jermzkwprk (beiybilvuh )
Positive
11 Oct 2023
Placebo
zwqaldlnvq(hgmogiymdc) = ziyufbrbmx jermzkwprk (beiybilvuh )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free